LNT and medical imaging: Siegel and colleagues provide cautionary perspective on evidence relating to the linear no-threshold hypothesis and review alternative dose–response models.
Page 1
Linear no-threshold background: Weber and Zanzonico offer additional insights into this controversial model for estimation of cancer induction risk and look at challenges to its application in diagnostic imaging.
Page 7
PSMA-targeted therapy: Eiber and Herrmann summarize recent advances and clinical trials of prostate-specific membrane antigen–targeted radioligand therapy in prostate cancer and preview a related article in this issue of JNM.
Page 9
PET/CT in colorectal cancer: Zukotynski and colleagues review recent restrictive guidelines on 18F-FDG PET/CT in colorectal cancer and detail evidence for the important role such imaging plays in determining both initial treatment strategy and subsequent management in some patients.
Page 11
PET/CT and lymphoma treatment response: Moghbel and colleagues provide an educational overview of data on the diagnostic and prognostic value of PET/CT for response assessment and pretransplant evaluation in lymphoma, with special emphasis on response-adapted therapy.
Page 13
Metabolic PET and PD: Meles and colleagues review recent clinical studies in 18F-FDG PET brain imaging in Parkinson disease, highlighting accompanying advances, differential diagnosis, prognosis, and treatment monitoring.
Page 23
Dual modality–based bombesin antagonist: Zhang and colleagues describe development and initial studies of a PET/CT and fluorescent probe that can be used for noninvasive imaging of gastrin-releasing peptide receptors overexpressed in prostate cancer.
Page 29
Preclinical 18F-FDOPA PET in insulinoma: Detour and colleagues investigate the effects of carbidopa on 18F-FDOPA uptake in insulinoma β-cells and in an insulinoma xenograft model in mice.
Page 36
PET and NSCLC glucose metabolism: Valtorta and colleagues use 18F-FDG PET to determine whether patient-derived non–small cell lung cancer xenografts reproduce in mice the metabolic glucose characteristics of corresponding parental tumors.
Page 42
177Lu-lilotomab satetraxetan tumor doses: Blakkisrud and colleagues develop dosimetric methods and calculate tumor-absorbed radiation doses for patients treated with this novel antibody radionuclide conjugate currently being tested in patients with relapsed CD37+ indolent non-Hodgkin lymphoma.
Page 48
177Lu-lilotomab satetraxetan red marrow dose: Blakkisrud and colleagues compare red marrow–absorbed doses for this novel antibody–radionuclide conjugate in 2 predosing arms of a phase 1/2a study in patients with CD37+ indolent B-cell non-Hodgkin lymphoma.
Page 55
PET and bendamustine–rituximab in MCL: Lamonica and colleagues assess the predictive value of 18F-FDG PET–assessed metabolic response to bendamustine–rituximab in patients with relapsed/refractory mantle cell lymphoma and compare results with those from conventional response criteria.
Page 62
Multiparametric imaging in HNSCC: Rasmussen colleagues investigate the feasibility, reproducibility, and data correlation of multiparametric integrated PET/MR imaging in patients with head and neck squamous cell carcinoma.
Page 69
NeoBOMB1 GRPR targeting: Nock and colleagues report on the biologic profiles of this potent gastrin-releasing peptide receptor antagonist labeled with 67/68Ga, 111In, and 177Lu in GRPR-expressing cells and mouse models, as well as initial PET/CT lesion visualization in men.
Page 75
PSMA PET and androgen receptor inhibition: Hope and colleagues evaluate the effect of androgen receptor inhibition on prostate-specific membrane antigen uptake imaged using 68Ga-PSMA-11 PET in a mouse xenograft model and in a patient with prostate cancer.
Page 81
177Lu-PSMA therapy safety and efficacy: Rahbar and colleagues detail the results of a large, multicenter study evaluating this promising agent for radioligand therapy in patients with metastatic castration-resistant prostate cancer.
Page 85
68Ga-DOTATATE and 18F-FDG PET/CT in NETs: Panagiotidis and colleagues compare the clinical impact of these 2 imaging tracers on management plans and prognoses in patients with histologically proven neuroendocrine tumors.
Page 91
Diabetes mellitus after PRRT: Umlauft and colleagues explore the risk of developing diabetes mellitus and its accompanying effects on all-cause mortality after somatostatin radiopeptide therapy for neuroendocrine tumors.
Page 97
PET dynamic range for MBF quantification: Renaud and colleagues propose new performance standard measurements to characterize the dynamic range of PET systems for accurate imaging in quantification of myocardial blood flow.
Page 103
11C-JNJ-42491293 mGluR2 tracer: Leurquin-Sterk and colleagues report on evaluation of this novel high-affinity radioligand as a selective metabotropic glutamate receptor-2–positive allosteric modulator tracer in rats, a primate, and humans.
Page 110
Overcoming BBB erlotinib efflux: Tournier and colleagues assess the efficacy of 2 different ABCB1/ABCG2 inhibitors to enhance brain distribution of 11C-erlotinib in nonhuman primates as a model of human blood–brain barrier efflux.
Page 117
123I-iodobenzovesamicol SPECT in DLB: Mazère and colleagues use this SPECT radiotracer targeting the vesicular acetylcholine transporter to evaluate the integrity of the 3 main cholinergic pathways as well as striatal cholinergic interneurons in patients with dementia with Lewy bodies.
Page 123
Epileptic activity and 18F-FET PET: Hutterer and colleagues describe a retrospective analysis using 18F-FET PET to investigate brain amino acid metabolism during epileptic seizures and to elucidate the associated pathophysiologic background.
Page 129
MMP imaging of lungs: Golestani and colleagues explore the feasibility of in vivo matrix metalloproteinase–targeted molecular imaging for detection of lung inflammation and remodeling in mice.
Page 138
Bacteria-specific tracers: Ordonez and colleagues detail a systematic approach that exploits unique biochemical pathways in bacteria to develop novel pathogen-specific imaging tracers with the potential to specifically detect and localize a broad range of bacteria, including multidrug-resistant organisms.
Page 144
RA therapy monitoring: van der Geest and colleagues assess whether a radiolabeled anti–fibroblast activation protein antibody can monitor the treatment efficacy of long-circulating liposomes containing prednisolone phosphate in a mouse model of rheumatoid arthritis.
Page 151
18F-SO3F− PET and NIS: Khoshnevisan and colleagues report on a search for new 18F-labeled human sodium–iodide symporter substrates offering higher specific activity, higher affinity, and simpler radiochemical synthesis than 18F-BF4−.
Page 156
89Zr-labeled pembrolizumab imaging: England and colleagues evaluate the pharmacokinetics, biodistribution, and dosimetry of this humanized monoclonal antibody targeting programmed cell death protein 1 in mice and rats.
Page 162
In vivo 3D REFT: Hu and colleagues describe 3D radiopharmaceutical-excited fluorescence tomography using europium oxide nanoparticles, which enhance Cerenkov luminescence signal intensity, improve penetration depth, and result in more accurate 3D radiopharmaceutical distribution.
Page 169
Anti-PSMA CLI: D’Souza and colleagues compare Cerenkov luminescence imaging with PET for evaluation of the in vivo behavior of anti–prostate specific membrane antigen antibody-based radiotracers.
Page 175
- © 2017 by the Society of Nuclear Medicine and Molecular Imaging.
Jump to section
Related Articles
Cited By...
- No citing articles found.